{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:26:48Z","timestamp":1792056408254,"version":"4.4.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.4158\/ep.14.1.18","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T22:03:13Z","timestamp":1365199393000},"page":"18-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Management of Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Dennis L.","family":"Andress","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Zangeneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart M.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP.14.1.18_bb0005","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1097\/01.ASN.0000034202.91413.EB","article-title":"The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease","volume":"13","author":"De Boer","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0010","first-page":"245","article-title":"Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure","volume":"49","author":"Panichi","year":"1998","journal-title":"Clin Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0272-6386(97)90086-X","article-title":"Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure","volume":"30","author":"Kates","year":"1997","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0020","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem-67-5-876","article-title":"Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure","volume":"67","author":"Pitts TO","year":"1988","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.14.1.18_bb0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ndt\/6.3.162","article-title":"Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism","volume":"6","author":"Reichel","year":"1991","journal-title":"Nephrol Dial Transplant."},{"issue":"Suppl 1","key":"10.4158\/EP.14.1.18_bb0030","first-page":"1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0035","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function--measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.1.18_bb0040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ki.1985.205","article-title":"Limitations of creatinine as a filtration marker in glomerulopathic patients","volume":"28","author":"Shemesh","year":"1985","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.mcna.2004.11.009","article-title":"Measurement of kidney function","volume":"89","author":"Stevens","year":"2005","journal-title":"Med Clin North Am."},{"issue":"Suppl 3","key":"10.4158\/EP.14.1.18_bb0050","first-page":"11","article-title":"KDOQI and the National Kidney Foundation. K\/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease [erratum in Am J Kidney Dis. 2006;48:518]","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 3","key":"10.4158\/EP.14.1.18_bb0055","first-page":"1","article-title":"National Kidney Foundation K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0060","series-title":"Physiology of the Human Kidney","author":"Wesson","year":"1969"},{"key":"10.4158\/EP.14.1.18_bb0065","series-title":"The Kidney: Structure and Function in Health and Disease","first-page":"520","article-title":"Comparative physiology of the kidney","author":"Smith","year":"1951"},{"key":"10.4158\/EP.14.1.18_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"10.4158\/EP.14.1.18_bb0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med."},{"issue":"Suppl 2","key":"10.4158\/EP.14.1.18_bb0080","first-page":"12","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","year":"2007","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0085","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1172\/JCI112714","article-title":"Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat","volume":"78","author":"Silver","year":"1986","journal-title":"J Clin Invest."},{"key":"10.4158\/EP.14.1.18_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ki.1997.297","article-title":"The hyperparathyroidism of chronic renal failure: a disorder of growth","volume":"52","author":"Parfitt","year":"1997","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0100","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1172\/JCI118701","article-title":"Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro","volume":"97","author":"Slatopolsky","year":"1996","journal-title":"J Clin Invest."},{"key":"10.4158\/EP.14.1.18_bb0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00041552-199707000-00004","article-title":"Regulation of parathyroid cell proliferation","volume":"6","author":"Silver","year":"1997","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.4158\/EP.14.1.18_bb0110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0115","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM199507203330307","article-title":"Renal osteodystrophy","volume":"333","author":"Hruska","year":"1995","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.1.18_bb0125","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","article-title":"Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management","volume":"35","author":"Block","year":"2000","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0130","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(01)01781-8","article-title":"Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?","volume":"39","author":"Raggi","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP.14.1.18_bb0135","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.1.18_bb0140","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/ndt\/13.8.2037","article-title":"Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism","volume":"13","author":"Ribeiro","year":"1998","journal-title":"Nephrol Dial Transplant."},{"key":"10.4158\/EP.14.1.18_bb0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfg513","article-title":"Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population","volume":"19","author":"Shoji","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"10.4158\/EP.14.1.18_bb0155","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.1.18_bb0165","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0170","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1525-139X.2005.18406.x","article-title":"Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease [erratum in Semin Dial. 2007;20:table of contents]","volume":"18","author":"Wolf","year":"2005","journal-title":"Semin Dial."},{"key":"10.4158\/EP.14.1.18_bb0175","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0180","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-136-8-200204160-00010","article-title":"Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition","volume":"136","author":"Remuzzi","year":"2002","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.14.1.18_bb0185","first-page":"7","article-title":"1,25-dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: effects of simultaneous protein and phosphorus restriction","volume":"25","author":"Lucas","year":"1986","journal-title":"Clin Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0190","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000098561","article-title":"Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease","volume":"27","author":"Zisman","year":"2007","journal-title":"Am J Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0195","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1046\/j.1523-1755.2001.00042.x","article-title":"p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium","volume":"60","author":"Cozzolino","year":"2001","journal-title":"Kidney Int."},{"issue":"90","key":"10.4158\/EP.14.1.18_bb0200","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jsbmb.2004.03.061","article-title":"1,25-Dihydroxyvitamin D downregulation of TGFalpha\/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure","volume":"89","author":"Dusso","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.4158\/EP.14.1.18_bb0205","first-page":"F454","article-title":"Rat calcium-sensing receptor is regulated by vitamin D but not by calcium","volume":"270","author":"Brown","year":"1996","journal-title":"Am J Physiol."},{"key":"10.4158\/EP.14.1.18_bb0210","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1345\/aph.1G724","article-title":"Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies","volume":"40","author":"Hudson","year":"2006","journal-title":"Ann Pharmacother."},{"key":"10.4158\/EP.14.1.18_bb0215","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/endo.133.3.8396012","article-title":"The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine","volume":"133","author":"Brown","year":"1993","journal-title":"Endocrinology."},{"key":"10.4158\/EP.14.1.18_bb0220","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","article-title":"A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia","volume":"26","author":"Slatopolsky","year":"1995","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0225","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","article-title":"Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport","volume":"139","author":"Brown","year":"2002","journal-title":"J Lab Clin Med"},{"key":"10.4158\/EP.14.1.18_bb0230","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jsbmb.2005.07.007","article-title":"Differential effects of Vitamin D analogs on bone formation and resorption","volume":"98","author":"Nakane","year":"2006","journal-title":"J Steroid Biochem Mol Biol."},{"key":"10.4158\/EP.14.1.18_bb0235","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1053\/ajkd.2000.17667","article-title":"Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro","volume":"36","author":"Balint","year":"2000","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0240","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0245","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/jn\/114.11.2043","article-title":"Antirachitic activity of 1 alpha-hydroxyergocalciferol and 1 alpha-hydroxycholecalciferol in rats","volume":"114","author":"Sj\u00f6den","year":"1984","journal-title":"J Nutr."},{"key":"10.4158\/EP.14.1.18_bb0250","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1523-1755.2002.kid573.x","article-title":"Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats","volume":"62","author":"Slatopolsky","year":"2002","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0255","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfg595","article-title":"Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure","volume":"19","author":"Rix","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"10.4158\/EP.14.1.18_bb0260","doi-asserted-by":"crossref","first-page":"16754","DOI":"10.1074\/jbc.M310271200","article-title":"Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis","volume":"279","author":"Panda","year":"2004","journal-title":"J Biol Chem."},{"key":"10.4158\/EP.14.1.18_bb0265","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archinte.1980.00330190042017","article-title":"Effects of long-term therapy with calcitriol in patients with moderate renal failure","volume":"140","author":"Healy","year":"1980","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP.14.1.18_bb0270","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0275","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ki.1992.404","article-title":"Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol","volume":"42","author":"Gallieni","year":"1992","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0280","first-page":"324","article-title":"Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism","volume":"43","author":"Dressler","year":"1995","journal-title":"Clin Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0285","first-page":"S43","article-title":"Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism","volume":"38","author":"Slatopolsky","year":"1992","journal-title":"Kidney Int Suppl."},{"key":"10.4158\/EP.14.1.18_bb0290","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0272-6386(96)90252-8","article-title":"Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism","volume":"28","author":"Malberti","year":"1996","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0295","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0300","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1210\/jcem-67-5-929","article-title":"Low dose calcitriol versus placebo in patients with predialysis chronic renal failure","volume":"67","author":"Nordal","year":"1988","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.14.1.18_bb0305","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","article-title":"Antiproteinuric effect of oral paricalcitol in chronic kidney disease","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0310","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0272-6386(99)70442-7","article-title":"Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation","volume":"33","author":"Keane","year":"1999","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0315","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0320","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmaco-dynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J Pharmacol Exp Ther."},{"key":"10.4158\/EP.14.1.18_bb0325","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.1.18_bb0330","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0335","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium \u00d7 phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int."},{"key":"10.4158\/EP.14.1.18_bb0340","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","article-title":"Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis","volume":"46","author":"Charytan","year":"2005","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP.14.1.18_bb0345","year":"2004","journal-title":"Thousand Oaks, CA: Amgen, Inc"},{"key":"10.4158\/EP.14.1.18_bb0350","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0355","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.02101205","article-title":"Association of disorders in mineral metabolism with progression of chronic kidney disease","volume":"1","author":"Schwarz","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.4158\/EP.14.1.18_bb0360","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20446786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20446786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/B730R3Q5364KQ318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:48:47Z","timestamp":1761515327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20446786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S1530891X20446786"],"URL":"https:\/\/doi.org\/10.4158\/ep.14.1.18","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.14.1.18","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}